Literature DB >> 19009564

Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis.

Xinqiang Huang1, Chaofeng Yang, Chengliu Jin, Yongde Luo, Fen Wang, Wallace L McKeehan.   

Abstract

Fibroblast growth factor (FGF) family signaling mediates cell-to-cell communication in development and organ homeostasis in adults. Of the FGF receptor (FGFR) isotypes, FGFR4 is the sole resident isotype present in mature parenchymal hepatocytes. FGFR1 that is normally associated with activated nonparenchymal cells appears ectopically in hepatoma cells. Ectopic expression and chronic activity of FGFR1 in hepatocytes accelerates diethylnitrosamine (DEN)-initiated hepatocarcinogenesis by driving unrestrained cell proliferation and tumor angiogenesis. Hepatocyte FGFR4 mediates liver's role in systemic cholesterol/bile acid and lipid metabolism and affects proper hepatolobular restoration after damage without effect on cell proliferation. Here we ask whether FGFR4 plays a role in progression of hepatocellular carcinoma (HCC). We report that although spontaneous HCC was not detected in livers of FGFR4-deficient mice, the ablation of FGFR4 accelerated DEN-induced hepatocarcinogenesis. In contrast to FGFR1 that induced a strong mitogenic response and depressed rate of cell death in hepatoma cells, FGFR4 failed to induce a mitogenic response and increased the rate of cell death. FGFR1 but not FGFR4 induced cyclin D1 and repressed p27 expression. Analysis of activation of Erk, JNK, and PI3K-related AKT signaling pathways indicated that in contrast to FGFR1, FGFR4 failed to sustain Erk activation and did not activate AKT. These differences may underlie the opposing effects of FGFR1 and FGFR4. These results suggest that in contrast to ectopic FGFR1 that is a strong promoter of hepatoma, resident FGFR4 that mediates differentiated hepatocyte metabolic functions also serves to suppress hepatoma progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19009564      PMCID: PMC2712883          DOI: 10.1002/mc.20494

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  49 in total

1.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.

Authors:  Takeshi Inagaki; Mihwa Choi; Antonio Moschetta; Li Peng; Carolyn L Cummins; Jeffrey G McDonald; Guizhen Luo; Stacey A Jones; Bryan Goodwin; James A Richardson; Robert D Gerard; Joyce J Repa; David J Mangelsdorf; Steven A Kliewer
Journal:  Cell Metab       Date:  2005-10       Impact factor: 27.287

2.  FGF-21 as a novel metabolic regulator.

Authors:  Alexei Kharitonenkov; Tatiyana L Shiyanova; Anja Koester; Amy M Ford; Radmila Micanovic; Elizabeth J Galbreath; George E Sandusky; Lisa J Hammond; Julie S Moyers; Rebecca A Owens; Jesper Gromada; Joseph T Brozinick; Eric D Hawkins; Victor J Wroblewski; De-Shan Li; Farrokh Mehrbod; S Richard Jaskunas; Armen B Shanafelt
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

3.  Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase.

Authors:  M Kan; X Wu; F Wang; W L McKeehan
Journal:  J Biol Chem       Date:  1999-05-28       Impact factor: 5.157

4.  Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis.

Authors:  Xinqiang Huang; Chundong Yu; Chengliu Jin; Chaofeng Yang; Rui Xie; Dongdong Cao; Fen Wang; Wallace L McKeehan
Journal:  Mol Carcinog       Date:  2006-12       Impact factor: 4.784

5.  Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis.

Authors:  Xinqiang Huang; Chundong Yu; Chengliu Jin; Masashi Kobayashi; Courtney A Bowles; Fen Wang; Wallace L McKeehan
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

6.  Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

Authors:  Rosanne St Bernard; Lei Zheng; Wei Liu; Daniel Winer; Sylvia L Asa; Shereen Ezzat
Journal:  Endocrinology       Date:  2004-11-24       Impact factor: 4.736

7.  Comparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells.

Authors:  S Raffioni; D Thomas; E D Foehr; L M Thompson; R A Bradshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

8.  Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis.

Authors:  Jun-Hyeog Jang
Journal:  Oncogene       Date:  2005-01-27       Impact factor: 9.867

9.  Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids.

Authors:  Chundong Yu; Fen Wang; Chengliu Jin; Xinqiang Huang; Wallace L McKeehan
Journal:  J Biol Chem       Date:  2005-03-04       Impact factor: 5.157

10.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.

Authors:  Fan Yang; Xiongfei Huang; Tangsheng Yi; Yun Yen; David D Moore; Wendong Huang
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

View more
  21 in total

Review 1.  Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.

Authors:  Matthew J Potthoff; Steven A Kliewer; David J Mangelsdorf
Journal:  Genes Dev       Date:  2012-02-02       Impact factor: 11.361

2.  FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.

Authors:  Xinle Wu; Hongfei Ge; Bryan Lemon; Steven Vonderfecht; Jennifer Weiszmann; Randy Hecht; Jamila Gupte; Todd Hager; Zhulun Wang; Richard Lindberg; Yang Li
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

3.  FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells.

Authors:  Ming-Min Chang; Meng-Shao Lai; Siou-Ying Hong; Bo-Syong Pan; Hsin Huang; Shang-Hsun Yang; Chia-Ching Wu; H Sunny Sun; Jih-Ing Chuang; Chia-Yih Wang; Bu-Miin Huang
Journal:  Cancer Sci       Date:  2018-10-23       Impact factor: 6.716

4.  Autophagy enhanced by microtubule- and mitochondrion-associated MAP1S suppresses genome instability and hepatocarcinogenesis.

Authors:  Rui Xie; Fen Wang; Wallace L McKeehan; Leyuan Liu
Journal:  Cancer Res       Date:  2011-10-28       Impact factor: 12.701

5.  Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.

Authors:  Yongde Luo; Chaofeng Yang; Weiqin Lu; Rui Xie; Chengliu Jin; Peng Huang; Fen Wang; Wallace L McKeehan
Journal:  J Biol Chem       Date:  2010-07-23       Impact factor: 5.157

6.  Glycosylation of FGFR4 in cholangiocarcinoma regulates receptor processing and cancer signaling.

Authors:  Andrew J Phillips; Marissa B Lobl; Yamnah A Hafeji; Hannah R Safranek; Ashley M Mohr; Justin L Mott
Journal:  J Cell Biochem       Date:  2022-01-04       Impact factor: 4.429

7.  Emerging roles of FGF signaling in hepatocellular carcinoma.

Authors:  Nana Zheng; Wenyi Wei; Zhiwei Wang
Journal:  Transl Cancer Res       Date:  2016-02       Impact factor: 1.241

Review 8.  Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Authors:  Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 9.  Metabolic Messengers: FGF21.

Authors:  Kyle H Flippo; Matthew J Potthoff
Journal:  Nat Metab       Date:  2021-03-18

10.  Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress.

Authors:  Chaofeng Yang; Weiqin Lu; Tao Lin; Pan You; Min Ye; Yanqing Huang; Xianhan Jiang; Cong Wang; Fen Wang; Mong-Hong Lee; Sai-Ching J Yeung; Randy L Johnson; Chongjuan Wei; Robert Y Tsai; Marsha L Frazier; Wallace L McKeehan; Yongde Luo
Journal:  BMC Gastroenterol       Date:  2013-04-17       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.